← Back to Clinical Trials
Recruiting NCT05341726

NCT05341726 BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05341726
Status Recruiting
Phase
Sponsor Columbia University
Condition Asthma
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2023-01-19
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
BREATHE InterventionControl Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2023-01-19 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is an efficacy-implementation trial to: 1. evaluate systematically the efficacy of BREATHE in 200 Black adults receiving care at urban federally qualified health centers (FQHCs) for uncontrolled asthma; and 2. identify multi-level barriers and facilitators to the widespread adoption and implementation of BREATHE in FQHCs.

Eligibility Criteria

Inclusion Criteria (participants): Patients participants will 1. be adults (\> or = 18 years of age) 2. self-report race as 'Black' race (African American, African, Caribbean, West Indian, multi-racial \[Black AND one or more additional races\]); identify their ethnicity as Hispanic OR non-Hispanic 3. have clinician-diagnosed persistent asthma (defined as being prescribed inhaled corticosteroids in the last 48 months) or have had an asthma exacerbation (e.g., ER visit, course of Prednisone) regardless of controller medicine use 4. receive asthma care at a partner FQHC and 5. screen positive for uncontrolled asthma as measured by the Asthma Control Questionnaire- 6 items (ACQ-6) and erroneous beliefs as measured by the Conventional and Alternative Management for Asthma (CAM-A) survey. Exclusion Criteria (participants): 1. non-English speaking 2. serious mental health conditions that preclude completion of study procedures or confound analyses or 3. participation in a listening session Inclusion Criterion (clinicians): 1\. those who manage a panel of adult asthma patients Inclusion Criteria (loved ones): 1. must be identified by patient participant as a loved one and 2. loved one must be a family member or friend of the patient participant. Exclusion Criteria (loved ones): 1. non-English speaking or 2. serious mental health conditions that preclude completion of study procedures or confound analyses

Contact & Investigator

Central Contact

Maureen George, PhD

✉ mg3656@cumc.columbia.edu

📞 2123051175

Principal Investigator

Maureen George, PhD

PRINCIPAL INVESTIGATOR

Columbia University School of Nursing

Frequently Asked Questions

Who can join the NCT05341726 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05341726 currently recruiting?

Yes, NCT05341726 is actively recruiting participants. Contact the research team at mg3656@cumc.columbia.edu for enrollment information.

Where is the NCT05341726 trial being conducted?

This trial is being conducted at Beacon, United States, Brooklyn, United States.

Who is sponsoring the NCT05341726 clinical trial?

NCT05341726 is sponsored by Columbia University. The principal investigator is Maureen George, PhD at Columbia University School of Nursing. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology